基本信息
浏览量:775
职业迁徙
个人简介
My current principal areas of research are:
prostate cancer aetiology (with a focus on metabolic factors such as the IGF system), predicting its progression and secondary and tertiary prevention of the disease via population-based screening and low-toxicity nutritional and lifestyle interventions;
the short- and long-term child and adult health effects of breastfeeding and early growth;
uncovering unexpected beneficial and adverse effects of commonly prescribed drugs through pharmaco-epidemiological studies based on automated clinical databases such as the UK GPRD.
prostate cancer aetiology (with a focus on metabolic factors such as the IGF system), predicting its progression and secondary and tertiary prevention of the disease via population-based screening and low-toxicity nutritional and lifestyle interventions;
the short- and long-term child and adult health effects of breastfeeding and early growth;
uncovering unexpected beneficial and adverse effects of commonly prescribed drugs through pharmaco-epidemiological studies based on automated clinical databases such as the UK GPRD.
研究兴趣
论文共 1063 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
EBioMedicine (2024): 105010
引用0浏览0引用
0
0
EBioMedicine (2024): 104991
引用0浏览0引用
0
0
Catherine Huntley,Lucy Loong, Corinne Mallinson, Rachel Bethell, Tameera Rahman, Neelam Alhaddad, Oliver Tulloch, Xue Zhou,Jason Lee, Paul Eves,Fiona McRonald,Bethany Torr,
EClinicalMedicine (2024): 102465
引用0浏览0引用
0
0
Trishna A. Desai,Asa K. Hedman,Marios Dimitriou,Mine Koprulu,Sandy Figiel,Wencheng Yin, Matthias Johansson,Eleanor L. Watts,Joshua R. Atkins, Aleksandr V. Sokolov,Helgi B. Schioth,Marc J. Gunter,
Cancer Researchno. 6_Supplement (2024): 7330-7330
BMJ Openno. 2 (2024): e075981-e075981
medrxiv(2024)
EBioMedicine (2024): 105010-105010
NEJM Evidenceno. 4 (2023): EVIDoa2300018-EVIDoa2300018
crossref(2023)
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn